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Abstract
Current concepts regarding the association between immunoglobulin (Ig) light chain structure and AL amyloidosis (AL)
emphasize Ig variable region amino acid substitutions because the majority of light chain amyloid fibrils that have been
sequenced contain amino termini of the variable region with only small amounts of the constant region. In this report, we
describe a patient with rapidly progressive AL whose amyloid deposits contained primarily monoclonal U light chain
constant region fragments. We sequenced and analyzed this AL protein, determining that it was an O18-O8 U1 variant and
that the constant region possessed an unusual SerCAsn substitution at position 177. Using pre-mortem bone marrow cells,
we cloned and sequenced the cDNA for this AL protein (HCAK1) and, using DNA from post-mortem somatic tissue, we
cloned and sequenced the patient’s U germline O18-O8 donor and U constant region (CU) gene segments. The cDNA that
coded for HCAK1 contained a variable region that was derived from O18-O8, showing 96.1% homology to germline, and a
CU that had a nucleotide substitution (AGC to AAC), resulting in the 177Ser!Asn replacement. Two CU genes were cloned
from somatic tissue DNA, one identical to a known CU sequence and another containing this substitution which likely is a
new CU allotype. Our findings indicate that further investigation is warranted into the contributions genetic polymorphisms
and light chain constant regions may make to amyloidogenesis. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Immunoglobulin U and V light chains are com-
posed of variable, joining and constant regions. In
AL amyloidosis (AL), ¢brillar deposits are usually
comprised of the amino termini of immunoglobulin
(Ig) light chain proteins with the constant region ei-
ther partially or entirely absent [1]. This has led to
intense study of AL light chain variable regions [2^4]
with limited investigation into the role of the con-
stant region [5,6].
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One model of amyloidogenesis postulates that re-
placement mutations in Ig light chain variable region
genes cause these light chain monomers to interact
ionically forming salt-bridges, stacks, ¢laments and
¢nally ¢brils under appropriate physiological condi-
tions [7]. The constant region of these proteins is not
characterized as being involved in the disease process
because of its nearly complete absence in most AL
¢brils. Why the constant region is generally absent
and whether it contributes to ¢bril formation is un-
known.
Recently, two AL U light chain proteins have been
found to be comprised of constant region fragments.
In the ¢rst case, the protein contained a substitution
of Asn for Ser at position 177, which was hypothe-
sized to be a new CU allele [8]. In the second case, the
AL protein had Ser at position 177, but was appar-
ently glycosylated [9]. These newly discovered con-
stant region fragment amyloid deposits point to a
possible contribution of the constant region to amy-
loidogenesis.
In our investigation into the disease process of a
patient with rapidly progressive AL, we extracted
and sequenced the Ig light chains from the amyloid
deposits and found mostly constant region frag-
ments, with minimal amounts of variable region frag-
ments. The constant region fragments contained the
177Ser!Asn substitution. Furthermore, using the po-
lymerase chain reaction (PCR) and standard cloning
techniques, we sequenced this patient’s complete ex-
pressed gene, as well as the germline genes from so-
matic tissue. This AL protein represents the second
case in which the position 177Ser!Asn substitution
occurs in association with a CU that forms amyloid.
2. Patient, materials and methods
2.1. Case history
The patient was a 55-year-old male radiologist
who was well until December, 1995, when he began
to experience early satiety and shortness of breath.
He sought medical attention and was diagnosed with
AL and multiple myeloma with cardiac, hepatic and
renal involvement in February 1996. His disease rap-
idly progressed and he died during attempted stem
cell harvest in May, 1996. Post-mortem was obtained
and showed massive deposits of amyloid ¢brils in all
major organs. We designate this patient’s protein as
HCAK1.
2.2. Amyloid protein isolation
Amyloid ¢brils were isolated from splenic tissue
known to contain amyloid by histologic preparation
and examination with Congo red staining. The ¢brils
were isolated using the classical water extraction
method [10]. Fibrils were suspended in 6 M guani-
dine hydrochloride, 0.5 M Tris, pH 8.5 containing
1 mg EDTA/ml, reduced with dithiothreitol and
alkylated with iodoacetic acid as previously described
[3]. Insoluble material was removed by centrifugation
and the supernatant was chromatographed on a
Sepharose CL6B column (2.6U90 cm), equilibrated
and eluted with 4 M guanidine hydrochloride, 0.05 M
Tris pH 8.2. Pooled fractions were dialyzed against
water and lyophilized.
2.3. Amyloid protein characterization
Samples were analyzed on SDS-PAGE by the pro-
cedure of Schagger and Von Jagow [11]. Sepharose
CL6B pooled fractions were digested with trypsin,
and the resulting peptides were fractionated on a
Beckman Ultrasphere ODS HPLC column
(0.46U25 cm) equilibrated with 0.1% tri£uoroacetic
acid and eluted with acetonitrile gradient as previ-
ously described [3]. Samples were sequentially de-
graded on an Applied Biosystems Model 473A Pro-
tein Sequencer using the manufacturer’s standard
cycles.
2.4. Nucleic acid preparation
RNA was extracted and cDNA was prepared from
aspirated bone marrow cells at initial evaluation of
the patient as previously described [12]. The cells
were treated with ammonium chloride to lyse red
blood cells, washed, pelleted, and cryopreserved at
380‡C. Using Trizol reagent (Gibco-BRL, Gaithers-
burg, MD), RNA was extracted from 106 to 107 cells
and cDNA was made (0.63 Wg Oligo[dT], 12.5 U
AMR Reverse Transcriptase (Promega, Madison,
WI), 5 mM MgCl2, Taq reaction bu¡er (Promega),
0.08 mM dNTP, and 49 U RNasin; 2 min at room
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temperature, 30 min at 42‡C then 1 min at 94‡C in a
thermal cycler; stored at 380‡C). DNA was ex-
tracted from frozen heart tissue (1U1U0.5 cm) using
the method of alkaline lysis, phenol/chloroform ex-
traction and ethanol precipitation [13].
2.5. Polymerase chain reaction (PCR)
PCR for Ig VL genes was performed on both mar-
row cDNA and heart DNA [12]. Brie£y, 25 pM of
each primer, 0.2 mM dNTp, Taq reaction bu¡er, 1 U
Taq polymerase (Perkin-Elmer, Roche Molecular
Systems, Branchburg, NJ), MgCl2, and 1 Wl cDNA
or DNA was brought up to 50 Wl and run in a ther-
mal cycler (2 min at 94‡C; 40 cycles of 1 min at
94‡C, 1 min at 50‡C for heart DNA or 58‡C for
bone marrow cDNA, 2 minutes at 72‡C; 10 minutes
at 72‡C). The primers used for the constant region of
HCAK1 were for a 5P CU primer [14] and a 3P con-
sensus primer designed based upon the protein se-
quence. All of the primers used in PCR are shown
in Table 1.
2.6. Cloning and sequencing
PCR products were subjected to cloning using the
TA Cloning Kit (Invitrogen, San Diego, CA). For
the expressed light chain cDNA, three separate
PCR products were used, and 12 colonies were
screened by EcoRI digest and electrophoresis, match-
ing the expected product size of 717 bp for the entire
light chain. Four clones of 327 bp from the heart
DNA matching the expected size for the constant
region alone, and two clones of 285 bp matching
the expected size for the variable region, were also
obtained. All clones were sequenced backwards and
forwards, and were globally aligned to con¢rm indi-
vidual sequence homology. Protein sequences were
deduced.
The variable and joining portions of the expressed
gene sequences were compared to the V Base Direc-
tory (www.mrc-cpe.cam.ac.uk/imt-doc/public/IN-
TRO.html) for determination of their most likely
germline origin. Additionally, the constant region
protein sequences of the ¢bril, germline, and ex-
pressed genes were compared to known CU sequences
[15] to determine the level of conservation of the
invariant residues. All of the protein sequences
were queried against the Genbank database
(www.ncbi.nlm.nih.gov/BLAST/) [16] and compared
to human sequences in the nr database to determine
their uniqueness.
3. Results
3.1. Protein sequence
Chromatography of reduced and alkylated ¢brils
on Sepharose CL6B revealed a major protein peak
eluting in the 10^17-kDa area, a minor peak in the
20^25-kDa area and a shoulder in the 5-kDa area.
Edman degradation analysis of the pooled major
peak indicated the presence of several peptides de-
rived from a U light chain. The changes and yields of
PTH-amino acids over 20 cycles were consistent with
the presence of a 3- to 4-fold molar excess of con-
stant region fragments over variable region peptides.
Approximately 25% of these fragments started with
Fig. 1. Amino sequence of (A) variable region and (B) constant
regions of a U1 amyloid protein HCAK1. The arrows indicate
the tryptic peptides used to determine the sequence. Peptide T4,
residues 43^45, was not found. Residues are numbered as in
Kabat et al. [15].
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residue 1 of a U1 light chain, 25% with residue 122,
and the remaining 50% with residues 109, 122, 117,
or 127 in equal amounts.
Analysis of the protein on SDS-PAGE showed
major bands of 10, 12 and 14 kDa, and minor bands
of 20 and 22 kDa. Sequence analysis after transfer to
PVDF membrane showed that: the 10 kDa band had
equimolar amounts of peptides starting with residue
1 and 127; the 12-kDa band had 50% starting at
residue 122, 20% each at residues 1 and 117, and
10% at residue 127; the 14-kDa band had 60% start-
ing at residue 109, 20% at residue 122, and the bal-
ance at residues 1, 112, and 117. The faint 20- and
22-kDa bands had U sequences starting at residue 62
and 46, respectively. The overall molar ratio of re-
covered variable region peptide to constant region
peptide was approximately 1:4 in agreement with
the above results. These data suggest that the major-
ity of the amyloid proteins consisted of CU fragments
starting with residues 109, 112, 117, 122, and 127,
and minor amounts of VU fragments starting with
residue 1.
The sequence of the amyloid fragments was deter-
mined by analysis of tryptic peptides after HPLC
fractionation. Analysis of ¢ve peptides determined
the sequence of residues 1^107 of the variable region
fragment except for three residues (Fig. 1A). Peptide
T4, residues 43^45, was not found in any of the iso-
lated HPLC factions. Peptides T9^T19 identi¢ed the
constant region sequence with a unique substitution
(Fig. 1B). Peptide T14 contained Asn-177 instead of
Ser-177. Several partial T9 peptides in addition to
full length were identi¢ed starting with residues
112, 117, and 122 in agreement with the results of
direct sequence analysis of the major peak. The re-
covery of constant region tryptic peptides was 6- to
7-fold greater than variable region tryptic peptides
suggesting that constant region fragments comprise
85% or more of the amyloid protein.
The minor CL6B peak (20^25 kDa) on SDS-
PAGE analysis showed the same protein bands as
the major peak plus bands at approximately 25 and
26 kDa, and weaker bands at higher molecular
weight. Edman sequence analysis of the pooled mi-
nor peak indicated that approximately 40% started
with residue 1 of a U1 light chain while the remainder
started with residues 109, 122, and 127 of CU. Anal-
ysis of HPLC fractionated peptides from a trypsin
digest of the minor peak showed that the constant
region comprised 60% or more of the pooled peak.
Peptide T14 contained only Asn-177 as in the major
peak.
Table 1
Primers used for PCR
Primer Sequence
5P Leader 5P-GAG CTC ATG GAC ATG
AGG GTC TCT GC-3P
5P FR1 5P-GAC ATC SWG ATG ACC
CAG TCT CC-3P
5P CU(reverse compliment) 5P-GAA GAC AGA TGG TGC
AGC CAC AGT-3P
5P CU 5P-ACT GTG GCT GCA CCA
TCT GTC TTC ATC TTC-3P
3P CU 5P-GTC GAC CTA RCA CTC
TCC CCT GTT GAA GCT-3P
Table 2
HCAK1 amino acid substitution analysis versus 233 known immunoglobulin light chain sequences from the Genbank nr database
Germline
substitutions
Total number
of identities
Number of Bence^Jones
or myeloma identities
Notes
N-30 (CDR1) s 25 NA Identity distribution was not analyzed for this position due
to the high number of identities.
T-43 (FR2) s 25 NA Identity distribution was not analyzed for this position due
to the high number of identities
G-50 (CDR2) 21 4 Two myeloma and two Bence^Jones proteins with identities
were obtained
I-72 (FR3) 1 1 One myeloma protein with an identity was obtained
NA, not analyzed.
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Analysis of the approximately 5-kDa shoulder on
the major peak by SDS-PAGE yielded a broad band
at 4^5 kDa. Sequence analysis of pooled shoulder
fractions yielded the sequence of defensin I with a
minor amount of N-terminal U1 sequence.
The sequence of the variable region of the amyloid
¢bril protein was con¢rmed to be of the U1 subtype
of the human Ig light chain family based upon its
close similarity to known germline deduced protein
sequences of this subtype in the V Base directory.
Furthermore, the protein sequence corresponded
most highly to the O18-O8 (DPK1) germline protein
sequence except for four amino acids, as shown in
Fig. 2, leading us to assign the variable region of
HCAK1 to this germline gene.
The pattern of amino acid substitutions in the
HCAK1 variable region as compared to O18-O8 is
similar to that found in other amyloidogenic U1 light
chains [2]. Upon comparison of the HCAK1 ¢bril
protein variable region with 233 known Ig light chain
variable regions by BLAST search (Table 2), we
found that two of the four amino acids that di¡ered
from the germline could be considered rare for their
position based upon their representation in other
known U light chains [16]. These rare amino acid
substitutions corresponded to some degree to se-
quences of known multiple myeloma and Bence^
Jones proteins (4 of 21 for G-50, and 1 of 1 for
I-72). Additionally, the joining region of the
HCAK1 ¢bril protein matched the JU4 germline se-
quence (LTFGGGTKVEIKR).
3.2. Gene sequences
Using DNA derived from somatic tissue, we
cloned and sequenced two germline O18-O8 genes
which corresponded exactly to published sequences.
The variable region of the expressed gene, HCAK1,
excluding leader, joining and constant region genes,
was 96.1% homologous to the germline sequence of
Fig. 2. A global alignment of known O18-O8 germline gene, patient O18-O8 germline gene, expressed HCAK1 gene, and the compari-
son of deduced protein sequences with the HCAK1 ¢bril protein sequence. The numbering is as in Kabat et al. [15]. Framework re-
gions (FR) are in bold, complementarity determining regions (CDR) are in normal type. Dashes represent identities for ease of read-
ing. The replacement mutations are at positions 30, 43, 50, and 72, while silent mutations are at positions 37, 56, 60, and 75.
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O18-O8. In addition, the variable region of the ex-
pressed gene was assigned by V BASE Dnaplot
alignment to the O18-O8 germline gene, con¢rming
the inference made on protein analysis. A global
alignment of the HCAK1 expressed variable region
and the patient’s O18-O8 germline variable region
gene sequences, and the deduced protein and amy-
loid protein sequences, are shown in Fig. 2. Genbank
accession numbers for the gene sequences are
AF113887-9. Using the method of Chang and Casali,
an analysis of the probability distribution of replace-
ment and silent mutations in the variable region of
HCAK1 indicates that the FR have been relatively
preserved (P = 0.06) while the CDR have not been
particularly subject to antigen selection (P = 0.30)
[17]. Speci¢cally, HCAK1 di¡ers from germline at
nucleotide 217 (ACT for ATT) creating the ThrCIle
at position 72, and at nucleotide 129 (ACC for GCC)
creating the AlaCThr at position 43. In addition to
these replacement mutations, there are also four si-
lent mutations as shown in Fig. 2.
In the expressed CU of HCAK1 cloned and se-
quenced from an RT-PCR amplicon, nucleotide
532 contains a point mutation (AAC) which di¡ers
from the Genbank CU germline sequence (AGC), and
all other CU sequences in the database [16]. This
mutation results in the 177Ser!Asn replacement.
DNA from genomic tissue was employed to identify
the patient’s CU germline sequence and four clones
were obtained (Fig. 3). Three of them contained the
expected and previously described CU germline se-
quence with an AGC coding for Ser at position
177. One clone contained adenine at nucleotide 532
instead of guanine, coding for Asn (AAC) at amino
acid position 177.
4. Discussion
The hypothesis that replacement mutations in the
variable regions of certain Ig light chains cause them
to be predisposed to form amyloid ¢brils discounts a
role for the constant region, not unreasonably since
except for the ¢rst few tryptic peptides constant re-
gions have generally not been found in amyloid de-
posits. In this report, however, we describe the sec-
ond instance of a CU that formed amyloid and had a
novel amino acid substitution at position 177 [8].
Our ¢ndings support the notion that some Ig light
chain constant regions contribute to amyloid forma-
tion.
Furthermore, we have cloned and sequenced the
gene that codes for this protein and have also cloned
and identi¢ed the germline genes of this AL U light
chain, HCAK1. Both the sequenced protein and the
protein sequence deduced from the expressed gene
show a novel amino acid at position 177 in CU. Hu-
man CU proteins have been shown to possess a lim-
ited degree of polymorphism with three de¢ned sero-
logic types that correspond to CU proteins that di¡er
by single amino acid replacements. However, all of
these allotypes possess Ser at position 177. From this
patient’s somatic tissue, we obtained two di¡erent CU
genes. Hence, our data indicate that this patient had
two CU germline genes.
These ¢ndings are consistent with the existence of
a new CU allotype with the 177Ser!Asn replacement
[8] ; however, they are also consistent with the possi-
bility that this substitution is the consequence of a
point mutation, particularly given the increased fre-
quency with which AGY serines mutate. In the case
of the former, the germline of this patient’s U locus
would be heterozygous for CU. In the case of the
latter, the somatic tissue would have been contami-
nated by clonotypic cells from the patient’s plasma
Fig. 3. The sequences of the constant region germline genes de-
rived from DNA from heart tissue are shown in A. Three of
four did not have the nucleotide change at position 532 (bold).
In B, the DNA plots are shown, with the normal Ser-177
(AGC) and the allelic variant with Asn-177 (AAC).
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cell clone, an implausible happenstance given the fact
that the overwhelming number of copies of germline
CU in the starting material would be derived from
somatic cells and the fact that only the O18-O8
germline gene (not the expressed mutated gene) was
cloned from the same starting material. Therefore,
we conclude that this patient was likely heterozygous
for CU. Of note, a similarity search from X-ray dif-
fraction studies in the Protein Data Bank at Brook-
haven National Laboratory (www.pdb.bnl.gov) re-
veals a human monoclonal antibody A5B7 with a
potentially similar tertiary structure as the CU of
HCAK1 [18]. Position 177 of A5B7 is located in
the middle of a L-sheet forming the framework of
the constant region. The change from Ser to Asn in
HCAK1 is a change towards hydrophilicity and po-
larity, which could create a more external domain
within the protein. Furthermore, the loss of the ^
OH in the Ser side-chain may e¡ect post-translation-
al modi¢cation or molecular interactions of the
folded protein.
Comparison of the VU of HCAK1 with published
AL sequences shows a similarity with BAN and rele-
vance to the view that self-association via salt-
bridges may play a role in initial monomer stacking
and ¢lament formation [3,7]. Like BAN, HCAK1
has an isoleucine (ATT) substituted for the germline
threonine (ACT) at position 72, placing a hydropho-
bic residue at a surface position two amino acids
away from Asp-70, an acidic residue on the same
aspect of the light chain as the antigen binding site.
Unlike BAN, but like other AL U1 proteins, HCAK1
retains the germline acidic residue Asp-28 in the
CDR1 region [4]. Interestingly, HCAK1 is among
the AL U1 proteins that do not have an Asp-50, a
residue that may be important for hypothetical pro-
amyloid ¢lament assemblies by salt-bridging with the
FR Lysine residues on facing light chain monomers.
Although HCAK1 is similar to BAN, the CU of
HCAK1 formed amyloid. What determines the por-
tions of the light chain that form amyloid, and how
or if the pattern of deposition relates to replacement
mutations in the variable region of these light chains,
remains unknown.
Furthermore, the speci¢c substitutions that occur
in the variable region of eleven AL U1 light chains
have previously been analyzed, showing little recog-
nizable pattern of substitution [4]. A comparison of
HCAK1 to normal human Ig light chains in the
Genbank nr database showed only two substitutions
which could be considered rare (Table 2). In addi-
tion, HCAK1 showed a high degree of homology to
germline with only four total replacement mutations
in the variable region (Fig. 2). Based upon a statis-
tical analysis of the distribution of these mutations
[17], HCAK1 probably did not encounter signi¢cant
antigenic challenge. Since it has been shown that
certain replacement mutations can potentially desta-
bilize VL and lead to in vitro aggregation when ex-
pressed in E. coli, it is possible that the basis for
amyloidogenicity is di¡erent in this case, involving
either non-speci¢c replacement mutations that lead
to improper folding or the novel CU or both [19,20].
Other cases in which Ig CU fragments were found
in amyloid deposits occurred in U3 and U4 light
chains with normal CU [9,21]. These patients appear
to have had indolent courses in comparison to the
patients reported with CU 177Ser!Asn. These cases
suggest that constant region fragment deposition
may be more frequently associated with CU than
CV fragments and that AL U light chains with CU
177Ser!Asn may be linked to rapid disease progres-
sion.
Current models of amyloid ¢bril formation hold
that replacement mutations in the Ig light chain var-
iable regions genes lead to conformational changes in
the encoded proteins that permit light chain variable
region aggregation [4,7]. Such views are based pri-
marily upon computer modeling of AL light chains,
as compared to the solved structure of normal light
chains, showing the potential for salt-bridge forming
regions [7]. Furthermore, other post-translational
events have been thought to be involved in amyloi-
dogenesis, including hydrogen bonding, dipole mo-
ment formation, charge^charge interactions, and gly-
cosylation [22]. We can now add the potential role of
the constant region to these interactions. Also, of
interest, defensin I was found in a shoulder peak of
the fractions isolated with HCAK1. This small cati-
onic peptide is an antimicrobial neutrophil product
involved in membrane permeabilization, character-
ized by a L-sheet structure [23]. It is unknown
whether this protein, most likely a contaminant, is
involved in amyloid deposition. However, since it is
not known when proteolysis of light chains occurs or
if light chain fragments found in the deposits are
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themselves amyloidogenic, the role of an exogenous
agent also remains speculative.
In conclusion, we describe a patient with AL
whose amyloid consisted almost entirely of novel
CU fragments containing a 177Ser!Asn substitution.
The patient’s marrow cDNA contained the novel
CU gene and somatic DNA contained both novel
and normal CU genes, lending support to the view
that the patient was heterozygous for CU and that
CU 177Ser!Asn is a new allelic polymorphism as de-
scribed by Solomon [8]. We believe that a re-thinking
of the role of light chain variable regions in amyloid
deposition is in order.
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